Skip to search formSkip to main contentSkip to account menu

Cyclosporine Ophthalmic Emulsion

An topical ophthalmic formulation containing cyclosporine, an undecapeptide produced by the fungus Beauveria nivea, with immunosuppressant and anti… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
Purpose To assess adherence, non-persistence, discontinuation, and switching of topical cyclosporine ophthalmic emulsion 0.05… 
2018
2018
Matrix Metalloproteinase 9 Point-of-Care Immunoassay Result Predicts Response to Topical Cyclosporine Treatment in Dry Eye Disease
Purpose We evaluate a matrix metalloproteinase-9 (MMP-9) point-of-care immunoassay (InflammaDry) as a prognostic tool for topical… 
2017
2017
Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
2014
2014
Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion.
Restasis is an ophthalmic cyclosporine emulsion used for the treatment of dry eye syndrome. There are no generic products for… 
Highly Cited
2012
Highly Cited
2012
A Randomized Double-Masked Study of 0.05% Cyclosporine Ophthalmic Emulsion in the Treatment of Meibomian Gland Dysfunction
Purpose: To compare the efficacy of topical cyclosporine [0.05% cyclosporine A (CsA)] and preservative-free artificial tears in… 
Highly Cited
2012
Highly Cited
2012
Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Highly Cited
2012
Highly Cited
2012
Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.
2011
2011
Cyclosporine 0.05% Ophthalmic Emulsion for Dry Eye in Korea: A Prospective, Multicenter, Open-Label, Surveillance Study
Purpose To assess the effectiveness and tolerability of cyclosporine ophthalmic emulsion (CsA) 0.05% in patients with moderate to… 
Review
2010
Review
2010
Impact of dry eye disease and treatment on quality of life
Purpose of review Recent increased awareness of dry eye disease (DED) by both clinicians and patients has been accompanied by… 
1998
1998
Preclinical safety studies of cyclosporine ophthalmic emulsion.
Cyclosporine A (CsA) is an immunomodulator that inhibits T-cell mediated immunoreactivity.1–4 In addition, data indicate that CsA… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)